Cancer Immunology Reserch

Cancer Immunol Res. 2026 May 28. doi: 10.1158/2326-6066.CIR-25-1300. Online ahead of print. ABSTRACT A hallmark of pancreatic cancer is an extensive fibroinflammatory stroma. Myeloid cells, including abundant macrophages, are a prevalent cellular component of the pancreatic cancer microenvironment and a key driver of immunosuppression. Identifying mechanisms of myeloid-cell driven immunosuppression is thus key to developing … Read more

Cancer Immunol Res. 2026 May 21:OF1-OF2. doi: 10.1158/2326-6066.CIR-26-0513. Online ahead of print. ABSTRACT Sex differences in antitumor immunity contribute to disparities in cancer outcomes, yet the role of CD4+ T helper cells in this context remains poorly understood. In this issue, Hunt and colleagues show that sex hormones restrain CD4+ T-cell help in males, weakening … Read more

Cancer Immunol Res. 2026 May 15. doi: 10.1158/2326-6066.CIR-25-1490. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in hematologic malignancies but remains limited in solid tumors because of the immunosuppressive microenvironment, tumor heterogeneity, poor immune-cell infiltration, and progressive T-cell dysfunction. Because cytokine costimulation is critical for maintaining T-cell fitness, … Read more

Cancer Immunol Res. 2026 May 13. doi: 10.1158/2326-6066.CIR-25-1240. Online ahead of print. ABSTRACT In hepatocellular carcinoma (HCC), stromal and immune components shape invasion and metastasis. To identify the cellular states that drive extracellular matrix (ECM) remodeling, define their organization at the tumor margin, and evaluate their association with prognosis, we profiled stromal regions at the … Read more

Cancer Immunol Res. 2026 May 11. doi: 10.1158/2326-6066.CIR-25-0691. Online ahead of print. ABSTRACT CD19-directed chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, up to 60% of patients do not achieve a complete response. To uncover determinants of therapeutic efficacy, we analyzed the … Read more

Cancer Immunol Res. 2026 May 6. doi: 10.1158/2326-6066.CIR-25-0662. Online ahead of print. ABSTRACT Immune checkpoint blockade (ICB) therapy is transforming non-small cell lung cancer (NSCLC) treatment and prolonging overall survival (OS). However, not all patients are responsive. Using computational cytometry analysis to identify immune cell subsets and early dynamic changes, we aimed to unravel the … Read more

Cancer Immunol Res. 2026 May 5. doi: 10.1158/2326-6066.CIR-25-1321. Online ahead of print. ABSTRACT Osteosarcoma (OS) responds poorly to immune-checkpoint blockade (ICB), and the molecular drivers of its immune-cold state remain unclear. Using multi-omics analyses, we identified an immune-cold OS subtype characterized by enrichment of protein SUMOylation and found the SUMO E1 subunit UBA2 as a … Read more

Cancer Immunol Res. 2026 May 4;14(5):715. doi: 10.1158/2326-6066.CIR-14-5-WWR. NO ABSTRACT PMID:42076931 | DOI:10.1158/2326-6066.CIR-14-5-WWR

Cancer Immunol Res. 2026 Apr 29. doi: 10.1158/2326-6066.CIR-25-1312. Online ahead of print. ABSTRACT The immunosuppressive tumor microenvironment (TME) contributes to resistance against checkpoint inhibitors. However, the precise factors that shape the immune contexture of the TME remain elusive. Here, we report that Single-Stranded DNA Binding Protein 4 (SSBP4), a previously uncharacterized protein, suppresses intratumoral T-cell … Read more

Cancer Immunol Res. 2026 Apr 28. doi: 10.1158/2326-6066.CIR-25-0534. Online ahead of print. ABSTRACT Loss-of-function STK11 mutations occur in 15-20% of lung adenocarcinomas (LUAD) and correlate with immunotherapy failure and worse survival. By integrating analysis of human tumor samples, a human LUAD cell line panel, and CCLE and TCGA datasets, we found that C3 production was … Read more